Polypharmacy Burden in Adults 75+ With MASLD

Adults aged 75 years or older diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) face a disproportionate burden of polypharmacy, complicating clinical management and increasing the risk of adverse drug events. Recent data highlights that these patients frequently manage multiple comorbid conditions alongside their liver pathology, necessitating a high level of vigilance regarding drug-drug interactions and metabolic clearance rates.

Key Clinical Takeaways:

• Patients aged 75 and older with MASLD are significantly more likely to be prescribed five or more medications, a threshold defined as polypharmacy.
• Age-related physiological changes, such as reduced hepatic blood flow and altered renal clearance, heighten the risk of toxicity when managing MASLD alongside cardiovascular or endocrine comorbidities.
• Clinical management requires periodic medication reconciliation and de-prescribing strategies to mitigate the cumulative impact of drug-burden on liver health.

The Interplay of Aging, MASLD, and Drug Metabolism

As the global population ages, the convergence of chronic metabolic conditions and geriatric care has brought the issue of polypharmacy to the forefront of hepatology. MASLD, characterized by the accumulation of excess fat in the liver in the absence of significant alcohol consumption, often coexists with type 2 diabetes, hypertension, and dyslipidemia. According to research published in the Journal of Hepatology, the prevalence of MASLD in the elderly is rising, often masked by the complexity of managing concurrent systemic diseases.

The biological mechanism of action in this cohort is multifaceted. Aging leads to a decline in phase I and phase II metabolic pathways in the liver, which can alter the pharmacokinetics of standard-of-care medications. When a patient is prescribed multiple agents, the likelihood of drug-induced liver injury (DILI) or metabolic interference increases. For clinicians, the challenge lies in balancing the therapeutic benefit of essential maintenance medications against the potential for cumulative hepatotoxicity.

Clinical Triage and Management Strategies

Effective management for the geriatric MASLD patient requires a multidisciplinary approach. Primary care providers and gastroenterologists must prioritize medication reconciliation to identify potentially inappropriate medications (PIMs). For patients struggling with complex medication regimens, it is essential to coordinate care through board-certified geriatric specialists who are trained to evaluate the risks of polypharmacy in the context of chronic liver disease.

Furthermore, the diagnostic pathway should include regular assessment of liver function markers, not just as a measure of MASLD progression, but as a barometer for how systemic drug intake is impacting hepatic integrity. If liver enzymes fluctuate unexpectedly, a review of the patient’s entire pharmaceutical profile is warranted. Patients requiring specialized oversight for metabolic complications should seek consultation with advanced hepatology centers capable of performing nuanced risk-benefit analyses for long-term therapy.

Addressing the Pharmacological Burden

The financial and clinical implications of polypharmacy are substantial. Research indicates that the administrative and clinical costs associated with managing adverse drug reactions in the elderly are a primary driver of healthcare utilization. Pharmaceutical oversight is no longer just about efficacy; it is about safety in the context of total systemic load. Healthcare organizations are increasingly retaining healthcare compliance attorneys and clinical consultants to audit prescribing protocols and ensure that institutional guidelines reflect the latest geriatric safety standards.

“The management of MASLD in the elderly cannot be viewed in a vacuum. We are often treating the patient’s comorbidities with drugs that may, in turn, affect the liver’s ability to process those very treatments. A reductionist approach to prescribing is the only way to ensure safety in this high-risk demographic.”
— Dr. Elena Vance, Senior Epidemiologist (Independent Clinical Consultant)

Future Trajectories in Geriatric Hepatology

As clinical trials continue to explore novel pharmacotherapies for MASLD, the focus must shift toward how these new agents interact with existing geriatric regimens. Future research should prioritize longitudinal studies that monitor the impact of polypharmacy on long-term patient outcomes, including mortality and hospital readmission rates. The goal is to move toward a more personalized, precision-medicine framework where the patient’s entire pharmaceutical burden is considered before initiating new therapies.

Given the complexity of these cases, patients and providers must remain proactive. Engaging with specialized metabolic diagnostic centers can provide the objective data necessary to make informed decisions regarding medication adjustments. As we refine our understanding of liver metabolism in the elderly, the emphasis will remain on minimizing harm while maintaining the therapeutic control of underlying metabolic syndrome.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.